12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CVac: Interim Phase II data

Interim data from the open-label, international Phase II CAN-003 trial 63 ovarian cancer patients in remission after first- or second-line therapy showed that CVac led to a median PFS of 365 days as of Aug. 17, 2012, vs. 321 days for observational standard of care. Median PFS for the first 7 patients enrolled in the trial that were not randomized and received CVac was 421 days. Median PFS for patients in remission after...

Read the full 345 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >